SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, a biotechnology company leveraging its brain-targeting chemistry platform, validated biology and biomarker-driven strategies to develop restorative ...
Clinical evidence of CNS target engagement observed at top dose in the MAD study is consistent with brain-activating thyroid effects and informs Phase 2 dose selection Phase 1 SAD and MAD package ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results